- Home
- GERN vs ARVN Comparison
GERN vs ARVN Comparison
Compare GERN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | ARVN |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.3M | 806.0M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GERN | ARVN |
|---|---|---|
| Price | $1.38 | $12.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 23 |
| Target Price | $3.00 | ★ $17.80 |
| AVG Volume (30 Days) | ★ 6.8M | 2.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $183,403,000.00 | ★ $312,300,000.00 |
| Revenue This Year | $147.34 | $11.06 |
| Revenue Next Year | $39.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 522.13 | 93.86 |
| 52 Week Low | $1.04 | $5.90 |
| 52 Week High | $4.05 | $24.77 |
Technical Indicators
Market Signals| Indicator | GERN | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 58.61 |
| Support Level | $1.21 | $12.47 |
| Resistance Level | $1.42 | $13.56 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 85.48 | 55.67 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.